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Abstract
Introduction: Lymph node metastases are a key prognostic factor in prostate cancer 
(PCa), but detecting lymph node lesions from PET/CT images is a subjective process 
resulting in inter-reader variability. Artificial intelligence (AI)-based methods can pro-
vide an objective image analysis. We aimed at developing and validating an AI-based 
tool for detection of lymph node lesions.
Methods: A group of 399 patients with biopsy-proven PCa who had undergone 
18F-choline PET/CT for staging prior to treatment were used to train (n = 319) and 
test (n = 80) the AI-based tool. The tool consisted of convolutional neural networks 
using complete PET/CT scans as inputs. In the test set, the AI-based lymph node de-
tections were compared to those of two independent readers. The association with 
PCa-specific survival was investigated.
Results: The AI-based tool detected more lymph node lesions than Reader B (98 vs. 
87/117; p = .045) using Reader A as reference. AI-based tool and Reader A showed 
similar performance (90 vs. 87/111; p = .63) using Reader B as reference. The number 
of lymph node lesions detected by the AI-based tool, PSA, and curative treatment 
was significantly associated with PCa-specific survival.
Conclusion: This study shows the feasibility of using an AI-based tool for automated 
and objective interpretation of PET/CT images that can provide assessments of 
lymph node lesions comparable with that of experienced readers and prognostic in-
formation in PCa patients.
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1  | INTRODUC TION
Detecting lymph node metastases is important for staging patients 
with newly diagnosed prostate cancer (PCa) and for managing pa-
tients with biochemically recurrent PCa. Reading PET/CT images is 
a subjective process, and the degree of experience and knowledge 
varies among physicians. Standards for reporting PCa molecular 
imaging have been proposed as a way to reduce the consequent 
variability both in clinical reporting and research (Eiber et al., 2018; 
Fendler et al., 2017). Alternatively, artificial intelligence (AI)-based 
methods can provide a quantitative assessment within seconds with 
reduced variability and high reproducibility, allowing more objec-
tive reporting. One such example is the bone scan index, which is 
an AI-based method offering an imaging biomarker that reflects the 
skeletal tumour burden in a reproducible way. In a large phase 3 mul-
ticentre clinical trial, this index has been shown to be an independent 
prognostic biomarker of survival in metastatic castration-resistant 
PCa (Armstrong et al., 2018).
In recent years, convolutional neural networks (CNNs) have rev-
olutionized the field of image analysis. The vision is that AI methods 
applied to whole-body PET/CT scans can provide a single number, 
the global disease score, to reflect the entire disease burden in the 
body or part of the body (Høilund-Carlsen et al., 2019). We have 
used CNNs to automatically detect and quantify PET tracer activity 
in the prostate gland and skeleton of patients with PCa (Lindgren 
Belal et al., 2017; Polymeri et al., 2020). Both methods provided 
volumetric measurements of tumour burden, which is associated 
with overall survival. An additional step towards a faster and com-
prehensive automated analysis that provides a global disease score 
in PCa patients is the detection and quantification of lymph node 
metastases. The challenge with lymph node detection compared to 
lesions in the prostate gland or skeleton is that the lymph nodes are 
not limited to an organ that can be segmented from the CT scan. 
Furthermore, the number of false positives that contain non-spe-
cific physiological radiotracer uptake and have a similar appearance 
is considerably larger and should be kept as low as possible without 
hampering sensitivity.
The aim of the present study was to explore the feasibility of 
using CNNs to detect lymph node metastases with PET/CT imaging 
in PCa patients. A secondary aim was to investigate the association 
between the number of automatically detected lymph node metas-
tases and PCa-specific survival.
2  | MATERIAL S AND METHODS
The AI-based tool consisted of two CNNs, the Detection CNN 
trained to detect lymph node lesions and the Organ CNN (Trägårdh 
et al., 2020) trained to segment organs. To classify an area of high 
tracer uptake as a lymph node lesion is, to a great extent, a question 
of ruling out any other explanation, for example, high uptake reflect-
ing normal uptake in the kidneys, liver, prostate or urinary bladder. 
Hence, a mask of the organs segmented by the Organ CNN was used 
as an auxiliary input to the Detection CNN (Figure 1). We examined 
this in a retrospective analysis of three patient cohorts all studied 
with 18F-choline.
2.1 | Patients
The Detection CNN was trained and tested with PET/CT scans from 
399 patients with biopsy-proven PCa. The PET/CT scans were ob-
tained for staging prior to treatment (androgen deprivation, radical 
prostatectomy or radiation therapy). The PCa patients had a median 
age of 69 years (range 42–89) and a median PSA of 21 ng/ml (range 
1.4–2,970). The Gleason score was six or less in 18 patients, seven 
in 145 patients, and eight or higher in 231 patients (missing data 
from five patients). A total of 279 PCa patients underwent curative 
treatment after PET/CT. The patients were retrospectively included 
from three prior studies focusing on PET/CT imaging in PCa; 42 pa-
tients from a study by Poulsen et al. (2014) at the Odense University 
Hospital in Denmark between March 2010 and May 2014; 399 pa-
tients from a study by Kjölhede et al. (2018) at the Skåne University 
Hospital in Sweden between February 2008 and November 2011; 
50 patients from a study by Mortensen et al. (2019) at the Odense 
University Hospital in Denmark between January 2013 and April 
2014. The patients were randomly divided into a training group (319 
patients; 80%) and a test group (80 patients; 20%).
The Organ CNN was trained on a separate group of 225 patients 
referred for PET/CT with known or suspected cancer other than 
PCa. Only the CT scans were used in the training process. The train-
ing group for the Organ CNN came from the Sahlgrenska University 
Hospital in Sweden.
2.2 | Ethics statement
All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional 
and/or national research committee (ethical approval was ob-
tained from the Regional Ethical Review Boards at Lund University 
(LU552/2007; Lindgren Belal et al., 2017), Gothenburg University 
F I G U R E  1   Schematic design of the AI-based tool. There are 
three inputs to the Detection CNN: the PET image, the CT image 
and an organ mask generated by the Organ CNN (Convolutional 
Neural Network)
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(295–08;2016/103) and Odense University (3–3013-1692/1; 
S-20120047) and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
2.3 | Imaging
The PET/CT scans were acquired with different integrated PET/
CT systems. The Sahlgrenska University Hospital used a Siemens 
Biograph 64 Truepoint, Skåne University Hospital used a Philips 
Gemini TF, and Odense University Hospital used Discovery VCT, 
Discovery STE, Discovery RX, and Discovery 690. PET images were 
acquired 1–1.5 hr after an intravenous injection of 18F-fluorocholine. 
The patients fasted for 6 hr prior to the administration of the tracer, 
and each patient received a dose of 4 MBq per kg body weight. 
Attenuation correction was based on the CT scan. The PET slice 
thickness was 3.27–4 mm. Low-dose CT scans (120 kV, 30–400 mAs, 
512x512 matrix) were obtained from the base of the skull to the 
mid-thigh. The CT slice thickness was 3–5 mm. The Organ CNN was 
trained on CT scans obtained without contrast whereas the 320 of 
the 399 patients used to train and test the Detection CNN were ob-
tained with intravenous and/or oral contrast agents.
2.4 | Manual annotations
The CNNs were trained with images and corresponding manual an-
notations. The Detection CNN used manually annotated lymph node 
lesions on the PET/CT scans of PCa patients. Two nuclear medicine 
specialists annotated the material; Reader A annotated all of the ma-
terial and was blinded to if the patients were part of the training or 
test group, and Reader B annotated the material of the test group 
and was blinded to the annotations by Reader A and the AI-based 
tool.
The instruction was to annotate uptake greater than background 
PET activity and judged by the reader to be consistent with a lymph 
node lesion and the CT component of the PET/CT was considered in 
this judgment. Thus, the images were interpreted in the same way 
as in clinical practice since no specific criteria for detection of lymph 
node lesions have been established.
The Organ CNN was trained using manually annotated bones 
(skull, mandible, vertebrae, sternum, scapulae, clavicles, humeri, 
ribs, hip bones and femurs) and soft tissue organs (brain, lungs, 
heart, aorta, liver, spleen, kidneys, prostate and urinary bladder) on 
CT scans.
A cloud-based annotation tool (RECOMIA, www.recom ia.org) 
was used for the annotation tasks. The Organ CNN was developed 
as a basic segmentation tool of RECOMIA and has been used in 
different studies (Lindgren Belal et al., 2017; Polymeri et al., 2020; 
Trägårdh et al., 2020).
2.5 | AI model
As mentioned above, our AI model was based on two convolutional 
networks. The Organ CNN segments a number of different organs 
and inputs an organ mask to the Detection CNN. Additionally, the 
Detection CNN also takes the CT and PET images as input (Figure 1). 
To simplify the structure, the PET image was resampled to the CT 
resolution.
Both networks use the same architecture which is described in 
Trägårdh et al., 2020, see Figure 2. The final convolutional layer of 
the Organ CNN has one channel per organ class with a softmax ac-
tivation. For the Detection CNN, the final convolutional layer has a 
single output channel with sigmoid activation. For each voxel, the 
output value describes the estimated probability of that voxel be-
longing to a lymph node lesion.
2.5.1 | Training the Organ CNN
The organ CNN was trained on the 225 manually segmented CT 
scans from the organ data set using a negative log-likelihood loss. 
As typical in machine learning, the images were divided 80–20 into 
a training set used for direct parameter estimation and a validation 
set used to tune hyperparameters. Optimization was performed 
F I G U R E  2   The structure of the convolutional neural network used both for the Organ CNN and the Detection CNN. Blue boxes are 
3 × 3×3 convolutional layers, and the number indicates the number of filters. Red boxes are 2×-upsampling layers, and yellow boxes are 
average pooling, where the number indicates the pool size. The effect of the pooling layers is that the network works on four different 
resolutions. This allows for a large receptive field with low memory cost during training. All convolutional layers use rectified linear unit 
activations, apart from the last one that uses a sigmoid activation to produce the final output probabilities.n
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using the Adam method with Nesterov momentum (Kingma & 
Adam, 2014). The learning rate was initialized to 0.0001 and re-
duced when the validation loss reached a plateau. After a few hours 
of training, the model was evaluated in the training group, and false 
positives were stored in a special group of hard examples that were 
sampled more frequently (10% of the samples) when the training 
was restarted.
2.5.2 | Training the Detection CNN
The lymph node lesions on the PET/CT scans manually annotated 
by Reader A were used for training. The Detection CNN was trained 
in the same way as the Organ CNN with one important difference. 
Since detection rather than the exact delineation of lymph node le-
sions is the focus of the AI-based tool, mimicking the exact bound-
aries of the annotations was not relevant. Thus, any voxels within 
10 mm of the annotated metastases were marked as “don't care.” 
This means that when computing the loss functions, there was no 
loss for these voxels regardless of the output label. For the remaining 
voxels, the standard negative log-likelihood loss was used. Naturally, 
this leads to a slight oversegmentation of the metastases. As detec-
tion was the main goal, this was considered acceptable.
2.6 | Statistical methods
The agreement between Readers A and B in classifying patients with 
and without lymph node lesions was evaluated using kappa values. 
The significance of a difference in true positive detection between 
the AI-based tool and Reader A/B was evaluated using McNemar's 
test.
Associations among the number of automatically detected 
lymph node lesions, number of manually detected lymph node le-
sions, age, PSA, curative treatment and PCa-specific survival were 
investigated using a univariate Cox proportional hazards regression 
model. Survival time was calculated from the date of the PET/CT 
scan. Hazard ratios (HRs) and 95% confidence intervals (CIs) were 
estimated. The level of significance was set at 0.05.
3  | RESULTS
The agreement was good between the two readers who indepen-
dently classified the 80 cases of the test group as positive or nega-
tive for the presence of lymph node lesions. In 18 of the 80 patients, 
both readers detected at least one lymph node lesion, and in 53 pa-
tients, they agreed that no lesion was present. The inter-reader reli-
ability, as measured by the kappa value, was 0.72 (95% confidence 
interval 0.56–0.89). Reader A detected 117 lesions in the test group 
and the AI-based tool detected 98 (84%) and Reader B 87 (74%) of 
these lesions (p = .045). Reader B detected 111 lesions and the AI-
based tool detected 90 (81%) and Reader A 87 (78%) of these lesions 
(p = .63). The AI-based tool detected one or more lymph node lesion 
in 71 of the 80 patients and classified only nine patients as negative 
for the presence of lymph node lesions. The agreement between the 
readers and the AI-based tool on a patient-by-patient level resulted 
therefore in low kappa values (0.08 and 0.11).
A total of 87 lymph node lesions were detected by both read-
ers. The AI-based tool detected 80 of these lesions (92%). Fifty-four 
lesions were detected by one of the two readers only, with the AI-
based tool detecting 28 of these lesions (52%). The AI-based tool 
made 219 detections not detected by any of the readers, corre-
sponding to 2.7 detections per patient. Most of these detections 
represented activity in lymph nodes not classified as abnormal by 
the readers (46%) or in the intestines (25%). In total, the AI-based 
tool made 327 detections, of which 108 (33%) were classified as 
lymph node lesions by at least one of the two readers.
Eight patients in the test group died during the follow-up due to 
PCa. Their median survival time was 5.1 years (range 1.4–7.0). The 
follow-up time for the remaining 67 patients was 5.2 years (range 
0.5–9.4). One patient was excluded from this analysis due to missing 
follow-up data. In the univariate Cox analysis, PSA, curative treat-
ment and number of lymph node lesions detected by Reader A, 
Reader B and the AI-based tool were significantly associated with 
PCa-specific survival. The results are shown in Table 1.
4  | DISCUSSION
The results of this study show that an AI-based tool can be trained 
to automatically detect lymph node lesions on PET/CT with sensitiv-
ity comparable with that of two experienced readers. Furthermore, 
the number of detected lesions was significantly associated with 
PCa-specific survival. The main clinical application for this type of 
AI-based tool in combination with corresponding tools for the au-
tomated quantification of tumour burden in the prostate gland and 
skeleton would be to perform a comprehensive, fast, automated and 
objective analysis and provide a global disease score for patients 
with PCa.
TA B L E  1   Univariate survival analysis demonstrating the 
associations among age, PSA, curative treatment, number of 






Age (years) 0.90 0.78–1.05 .19
PSA (ng/ml) 1.02 1.003–1.04 .02
Curative treatment 0.16 0.03–0.82 .03
Number of lymph 
nodes—Auto
1.19 1.05–1.33 .005
Number of lymph nodes—
Reader A
1.46 1.18–1.80 .0005
Number of lymph nodes—
Reader B
1.14 1.03–1.26 .01
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Giovacchini and colleagues showed that 11C-choline PET/CT pre-
dicts PCa-specific survival (Giovacchini et al., 2019). In their study, 
the PET/CT scans were visually interpreted as positive or negative, 
whereas AI-based tools can provide quantitative assessments of 
the tumour burden. Additional clinical information is most likely ob-
tained from quantitative assessments of tumour burden compared 
with simply classifying the scans as “positive” or “negative.” The 
addition of improved reproducibility compared to interpretations 
by various physicians and significantly reduced reading times by di-
rectly highlighting possible true detections shows that the clinical 
benefit of the AI-based approach is even more apparent.
Our results illustrate the inter-observer variability associated with 
the detection of lymph node metastases and that an AI-based tool 
performs at least as well as an experienced nuclear medicine specialist 
in reproducing other specialists’ detections. Considerable inter-reader 
variability in the interpretation of PET/CT scans has been reported. 
For example, Kluge et al. had five nuclear medicine experts with spe-
cial expertise in PET/CT imaging of Hodgkin's lymphoma score interim 
PET/CT scans of 100 patients, which resulted in an inter-reader kappa 
value as low as 0.42 (Kluge et al., 2016), demonstrating the need for 
much more reliable and reproducible analysis methods.
The main limitation to the sensitivity of PET/CT scans for 
lymph node lesion detection is that an estimated 150–300 mil-
lion metastatic cells need be present to be detected by PET (Alavi 
et al., 2019); thus, theoretically, micro-metastases will be missed by 
this technique. Arguably, deep histological analyses could detect the 
micro-metastases missed by PET/CT. However, performing these 
analyses on a routine basis would greatly increase the associated 
costs and time needed, since histopathologic examinations of lymph 
nodes normally comprise only 1%–2% of the relevant lymphatic tis-
sue (Engvad et al., 2014).
Our study demonstrated the feasibility of using AI-based meth-
ods for the detection of lymph node lesions using choline-based 
tracers. However, as stated earlier, PSMA is a more sensitive tracer 
than choline, and these choline tracers are therefore being phased 
out in favour of PSMA-associated tracers (Ghafoor et al., 2019; Hope 
et al., 2019). There are differences in physiological uptake between 
choline and PSMA that need to be considered, but the similarities in 
the process to detect lymph nodes with high tracer uptake are very 
similar, and the organ masks trained by different CNNs would be the 
same for both tracers. It is therefore likely that CNNs can be trained 
to detect lymph node lesions based on training sets consisting of 
PSMA PET/CT scans.
We realize that only one nuclear medicine specialist and a limited 
training group were used to train our AI-based tool in our study. The 
good results in the separate test set show the feasibility of using AI-
based tools for this type of image analysis and larger training groups 
with a more elaborated gold standard would most likely result in 
an even better AI-based tool. It should also be noted that the AI-
based tool managed to handle PET/CT studies acquired with differ-
ent cameras at different hospitals, indicating that it will be possible 
to develop AI-based tools that can be widely used irrespective of 
the clinical setting. Furthermore the Organ CNN was trained using 
CT studies without contrast while 80% of the CT studies of the 
Detection CNN were acquired with contrast. The performance of 
the AI-based tool would most likely improve if CT studies with con-
trast also were used to train the Organ CNN.
A weakness of the study was that the performance of the tool 
in the test group was compared to readings of two nuclear medicine 
specialists and not to histopathologic findings. Nevertheless, we were 
able to demonstrate that the number of lymph node lesions detected 
by the AI-based tool was significantly associated with PCa-specific 
survival despite only a few terminal events. The AI-based made false 
detections for example representing activity in the intestines. This 
problem will be addressed in future development or our tool.
5  | CONCLUSION
We have shown that an AI-based tool can be trained to automatically 
detect lymph node metastases on PET/CT with sensitivity compa-
rable with that of two experienced readers and that the number of 
detected lesions was significantly associated with PCa-specific sur-
vival. Future work will include efforts to decrease the rate of false 
detections by the tool, but this is a first step in the development 
towards clinically useful AI-based tools that can provide comprehen-
sive and objective assessments of tumour burden in PCa patients 
based on PET/CT.
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